Roche signs deal with Eleven Bio
Roche has bagged access to Eleven Biotherapeutics’ eye disease candidate EBI-031 in a deal worth around $270 million.
Read More
Tag: EBI-031
Roche bags Eleven’s experimental eye disease drug
Roche has snapped up rights to an experimental eye disease drug and technology from US biotech Eleven Biotherapeutics in a deal that be worth $270 million.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
